ARWR

NASDAQ 已收盘

Arrowhead Pharmaceuticals

43.65 USD
▲+0.54+1.25%
盘后 47.30 0.00%
2026-11-19
市值
$6.07B
市盈率
—
EPS
-5.11
股息率
—
52 周区间
37.06 – 95.49
成交量
2.56M
Beta
1.37
目标价
105.86
52W 低 37.0652W 高 95.49
价格走势

公司简介

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...